Here’s Why Ketamine Is Different Than Any Other Psychedelic
Last reviewed and updated: June 26, 2026.
Key Takeaways
| Mechanism | Ketamine = NMDA glutamate receptor antagonist (dissociative); classical psychedelics = 5-HT2A serotonin receptor agonist. Completely different neurochemistry. |
| Experience | Ketamine: floating, out-of-body dissociation, dreamlike. Classical psychedelics: enhanced perception, emotional depth, visual alterations, possible ego dissolution. |
| Legal status | Ketamine Schedule III, accepted medical use, Spravato FDA-approved. Classical psychedelics mostly Schedule I federally; psilocybin legal only in OR/CO supervised settings. |
| Duration | Ketamine IV: 40–60 min. Psilocybin: 4–6 hrs. LSD: 8–12 hrs. MDMA: 4–6 hrs. Practical for clinic scheduling and cost. |
| Clinical status now | Ketamine/Spravato: mainstream psychiatric practice today. Psilocybin: Phase 3 positive, NDA approaching 2026–2027. LSD: Phase 3 positive June 2026. MDMA: FDA rejected 2024, multi-year runway. |
Anyone who has dived into psychedelic experiences knows that no two drugs are created equally. Yes, some hallucinogen drugs produce similar results, but they differ depending on a number of different factors. And as more ketamine clinics continue to open around the world — a sure sign that the alternative treatment is becoming more socially acceptable — we explain why ketamine differs from other psychedelics.
To help us identify reasons why ketamine differs from other psychedelics, we lean on the knowledge and experience of Healing Maps’ resident neuroscientist, Zeus Tipado, who explains in the video how ketamine compares (and is different) from psychedelics like ayahuasca, psilocybin mushrooms, MDMA, and more.
RELATED: Ketamine Experiences: What Happens If It Doesn’t Work?
As Zeus states, ketamine is not a serotonergic agonists — instead being a NMDA antagonist — which is part of the reason why ketamine differs from other psychedelics.
For instance, if LSD and the brain act like tiny keys opening up serotonin receptors like locks, ketamine is like jamming these locks so that it’s impossible for a “key” to open up. This is is part of the reason why some experts don’t believe ketamine is a psychedelic.
There are supporting studies about the positive effects ketamine has on mental health issues. These include using ketamine for depression and ketamine for anxiety. And while there’s still plenty to understand, the video above helps explain why ketamine differs from other psychedelics — even if it acts in many unique ways.
Check out more information on psychedelics by following Healing Maps on YouTube, Instagram and Facebook.
Ketamine vs. Classical Psychedelics: A Current Comparison
The distinction between ketamine and classical psychedelics is not just pharmacological trivia — it has real implications for legality, access, clinical application, and the subjective experience people should expect. As both ketamine and classical psychedelics have expanded in public awareness and clinical use over the last few years, this comparison has become increasingly practical for patients, providers, and curious observers trying to make sense of the landscape.
Mechanism: completely different neurochemistry. Classical psychedelics — psilocybin, LSD, DMT, mescaline — work primarily through agonism at the serotonin 2A (5-HT2A) receptor. They mimic serotonin at a receptor that regulates perception, cognition, and mood, producing altered visual perception, enhanced emotional sensitivity, ego dissolution, and the “connected” or mystical quality that characterizes classical psychedelic experiences. Ketamine works through a completely different mechanism: NMDA receptor antagonism in the glutamate system. Glutamate is the brain’s primary excitatory neurotransmitter, and blocking NMDA receptors produces dissociation — the feeling of detachment from one’s body and ordinary perception — along with rapid effects on neural plasticity and mood that are responsible for ketamine’s antidepressant action. These are not variations on the same theme; they are categorically different drugs acting on different receptor systems with different subjective profiles and clinical applications. MDMA — sometimes grouped with psychedelics informally — is yet a third distinct mechanism: it works through monoamine release (serotonin, dopamine, norepinephrine), not through 5-HT2A agonism or NMDA antagonism.
Legal status: the most practically significant difference. Ketamine is a Schedule III controlled substance with accepted medical use in the United States — it has been legally prescribed since the 1970s as an anesthetic. IV ketamine for depression is off-label but legal to prescribe; Spravato (esketamine nasal spray) is FDA-approved for treatment-resistant depression and major depressive disorder with suicidal ideation. Insurance covers Spravato in qualifying cases. Classical psychedelics — psilocybin, LSD, DMT, mescaline, ibogaine — are Schedule I federally, meaning no accepted medical use and high abuse potential in the eyes of the federal government. The only legal supervised psilocybin access in the U.S. is in Oregon (facilitated services since 2023) and Colorado (since 2024), through state-level frameworks that operate independently of federal scheduling. MDMA, also Schedule I, has had its therapeutic application rejected by the FDA (2024) and has no legal clinical pathway currently. The practical implication: if you need a psychedelic-adjacent treatment today with insurance coverage and a physician prescription, ketamine is the only option.
Duration, experience, and clinical use context. The timeline differences are clinically relevant: IV ketamine sessions last approximately 40–60 minutes; intramuscular ketamine 60–90 minutes. Psilocybin sessions typically last 4–6 hours; LSD 8–12 hours; MDMA 4–6 hours; ayahuasca 4–8 hours or longer. This has direct implications for clinic scheduling, staffing, and cost. The experiential quality also differs: ketamine produces a dissociative state characterized by floating, out-of-body sensations, and distortion of time and space — often described as dreamlike or anesthetic-adjacent. Classical psychedelics produce altered visual perception, enhanced emotional depth, and in higher doses, ego dissolution or mystical-type experiences. The clinical landscape is changing fast: psilocybin (Compass COMP360) has two positive Phase 3 trials and is on track for NDA submission; LSD (MindMed DT120) reported positive Phase 3 data in June 2026; psilocybin therapy may enter mainstream psychiatric practice within 1–2 years, making this comparison increasingly practical rather than hypothetical.
Frequently Asked Questions
Is ketamine a psychedelic?
Technically and pharmacologically, no — though the answer depends on how you define “psychedelic.” Ketamine is a dissociative anesthetic that produces altered consciousness through NMDA receptor antagonism in the glutamate system. Classical psychedelics produce altered consciousness through serotonin 2A receptor agonism — an entirely different mechanism. The subjective experiences are also distinct: classical psychedelics tend toward enhanced perception, emotional depth, and visual alterations; ketamine produces dissociation, out-of-body experiences, and detachment from ordinary reality. In popular usage, “psychedelic” is sometimes used loosely to mean any substance that produces altered consciousness, which is why ketamine sometimes gets grouped in. Clinicians and researchers typically keep the pharmacological distinction clear: ketamine is a dissociative, not a psychedelic.
How is ketamine different from psilocybin?
Ketamine and psilocybin differ across nearly every relevant dimension. Mechanism: ketamine blocks NMDA glutamate receptors (dissociative); psilocybin activates serotonin 2A receptors (psychedelic). Duration: ketamine IV lasts 40–60 minutes; psilocybin lasts 4–6 hours. Legal status: ketamine is Schedule III with legal medical uses and FDA-approved forms (Spravato); psilocybin is Schedule I federally with legal supervised access only in Oregon and Colorado. Experience: ketamine produces floating, disconnection, and dreamlike dissociation; psilocybin produces enhanced perception, emotional openness, visual alterations, and often mystical-type experiences at higher doses. Clinical status: ketamine is already in mainstream psychiatric practice; psilocybin has two positive Phase 3 trials and is approaching NDA submission, potentially entering mainstream practice within 1–2 years.
Which is safer: ketamine or psilocybin?
Both have favorable safety profiles in supervised clinical contexts, but they carry different risk profiles. Ketamine’s primary risks are: dissociation and confusion during acute effects (managed in clinic settings), blood pressure elevation, and with repeated use, cystitis (bladder inflammation) and psychological dependence potential — it is a controlled substance with abuse potential. Psilocybin’s primary risks are: psychological distress during acute experiences (particularly at high doses or in unsupported settings), rare triggering of latent psychiatric conditions in susceptible individuals (though this risk is substantially mitigated by screening in clinical trials), and challenging experiences that require good set, setting, and support. Psilocybin has no known lethal dose in humans and does not produce physical dependence. Neither is without risk; both have safety records that compare favorably to many approved psychiatric medications when used in supervised clinical contexts. The comparison is less about which is “safer” in the abstract than about which is appropriate for a specific person’s situation, history, and treatment goals.
Can ketamine and psilocybin be combined?
Combining ketamine and psilocybin is not a studied or clinically sanctioned practice — there are no published clinical trials examining this combination, and combining dissociatives with psychedelics carries unpredictable risks including extreme psychological overwhelm, increased cardiovascular stress, and difficulty managing the experience. In underground or retreat contexts, some people have reported using them in sequence (psilocybin session with ketamine used separately for integration), but this is outside any established clinical framework. As both compounds approach mainstream medical availability, the emerging guidance is to use them in clearly defined clinical contexts with proper screening, preparation, and integration support — not in combination. Anyone considering either compound should work with a qualified provider rather than experimenting independently.
